Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia

Bone Marrow Transplantation volume 28, pages 895–897 (2001)Cite this article

Abstract

Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that has recently become available for use in patients with relapsing or refractory acute myeloid leukemia. Reversible hepatotoxicity is common after administration. We describe the first report of hepatic veno-occlusive disease (HVOD) developing after Mylotarg infusion in a patient who underwent hematopoietic stem cell transplantation 8 months earlier. Certain antineoplastic agents have been implicated as a cause of HVOD, but the disease is most commonly seen within 30 days after hematopoietic stem cell transplantation. The possible association between Mylotarg infusion and HVOD is discussed. Bone Marrow Transplantation (2001) 28, 895–897.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Sievers EL, Applebaum FR, Spielberger RT et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678–3684

    CAS  PubMed  Google Scholar 

  2. Sievers EL, Larson RA, Estey E et al. Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse Blood 1998 92 (Suppl. 1): 613a (Abstr.)

    Google Scholar 

  3. Richardson P, Guinan E . The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches Br J Haematol 1999 107: 485–493

    Article  CAS  Google Scholar 

  4. Feldman M, Sleisenger MH, Scharschmidt BF (eds). Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management, 6th edn WB Saunders Company: Philadelphia 1998

    Google Scholar 

  5. Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 1995 85: 3005–3020

    CAS  Google Scholar 

  6. Appelbaum FR . Antibody-targeted therapy for myeloid leukemia Semin Hematol 1999 36 (Suppl. 6): 2–8

    Google Scholar 

  7. Anon Celltech/Wyeth to file CMA 676NDA in third quarter FDC Reports: The Pink Sheet 1999 61: 18–19

  8. Sato Y, Asada Y, Hara S et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation Histopathology 1999 34: 66–70

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA

    DK Tack, L Letendre & A Tefferi

  2. Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, MN, USA

    PS Kamath

Authors
  1. DK Tack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Letendre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. PS Kamath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Tefferi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tack, D., Letendre, L., Kamath, P. et al. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant 28, 895–897 (2001). https://doi.org/10.1038/sj.bmt.1703242

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703242

Keywords

This article is cited by

Search

Advanced search

Quick links